872 related articles for article (PubMed ID: 33982973)
1. Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.
Ma T; Wu M
Am J Gastroenterol; 2021 Apr; 116(4):848-849. PubMed ID: 33982973
[No Abstract] [Full Text] [Related]
2. Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
Freedberg DE; Conigliaro J; Wang TC; Tracey KJ; Callahan MV; Abrams JA;
Gastroenterology; 2020 Sep; 159(3):1129-1131.e3. PubMed ID: 32446698
[No Abstract] [Full Text] [Related]
3. Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
Chenchula S; Ray A; Sadasivam B
Drug Res (Stuttg); 2021 Jul; 71(6):295-301. PubMed ID: 33757133
[TBL] [Abstract][Full Text] [Related]
4. Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?
Amjad W; Malik A
Am J Gastroenterol; 2021 Jul; 116(7):1561. PubMed ID: 34183586
[No Abstract] [Full Text] [Related]
5. Histamine receptors and COVID-19.
Ennis M; Tiligada K
Inflamm Res; 2021 Jan; 70(1):67-75. PubMed ID: 33206207
[TBL] [Abstract][Full Text] [Related]
6. Famotidine and Mortality in Coronavirus Disease 2019.
Sethia R; Prasad M; Garg PK
Gastroenterology; 2021 Jul; 161(1):361-362. PubMed ID: 33388317
[No Abstract] [Full Text] [Related]
7. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study.
Zhou J; Wang X; Lee S; Wu WKK; Cheung BMY; Zhang Q; Tse G
Gut; 2021 Oct; 70(10):2012-2013. PubMed ID: 33277346
[No Abstract] [Full Text] [Related]
8. Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.
Kow CS; Abdul Sattar Burud I; Hasan SS
Mayo Clin Proc; 2021 May; 96(5):1365-1367. PubMed ID: 33958065
[No Abstract] [Full Text] [Related]
9. Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.
Sun C; Chen Y; Hu L; Wu Y; Liang M; Ayaz Ahmed M; Bhan C; Guo Z; Yang H; Zuo Y; Yan Y; Zhou Q
Dig Dis Sci; 2021 Nov; 66(11):3929-3937. PubMed ID: 33625613
[TBL] [Abstract][Full Text] [Related]
10. In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.
Lavie CJ
Mayo Clin Proc; 2021 May; 96(5):1367-1368. PubMed ID: 33958066
[No Abstract] [Full Text] [Related]
11. Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis.
Chiu L; Shen M; Lo CH; Chiu N; Chen A; Shin HJ; Prsic EH; Hur C; Chow R; Lebwohl B
PLoS One; 2021; 16(11):e0259514. PubMed ID: 34735523
[TBL] [Abstract][Full Text] [Related]
12. No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis.
Cheema HA; Shafiee A; Athar MMT; Shahid A; Awan RU; Afifi AM; Shah J; Jalal PK
J Infect; 2023 Feb; 86(2):154-225. PubMed ID: 36462586
[No Abstract] [Full Text] [Related]
13. Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study.
Cheung KS; Hung IFN; Leung WK
Gastroenterology; 2021 Apr; 160(5):1898-1899. PubMed ID: 32682763
[No Abstract] [Full Text] [Related]
14. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Janowitz T; Gablenz E; Pattinson D; Wang TC; Conigliaro J; Tracey K; Tuveson D
Gut; 2020 Sep; 69(9):1592-1597. PubMed ID: 32499303
[TBL] [Abstract][Full Text] [Related]
15. Famotidine in the management of schizophrenia.
Martinez MC
Ann Pharmacother; 1999 Jun; 33(6):742-7. PubMed ID: 10410190
[TBL] [Abstract][Full Text] [Related]
16. What Underlies the Benefit of Famotidine Formulations Used During COVID-19?
Singh VP; El-Kurdi B; Rood C
Gastroenterology; 2021 Apr; 160(5):1899-1900. PubMed ID: 32777281
[No Abstract] [Full Text] [Related]
17. Famotidine and Coronavirus Disease 2019.
Freedberg DE; Wang TC; Abrams JA
Gastroenterology; 2021 Jul; 161(1):360-361. PubMed ID: 33387529
[No Abstract] [Full Text] [Related]
18. Angioedema, ACE inhibitor and COVID-19.
Grewal E; Sutarjono B; Mohammed I
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32912894
[TBL] [Abstract][Full Text] [Related]
19. No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews.
Li W; Dong Y; Lei X
Dig Dis Sci; 2022 Jan; 67(1):351-353. PubMed ID: 34471967
[No Abstract] [Full Text] [Related]
20. [Clinical aspects of Kvamatel (famotidine) administration].
Golochevskaia VS
Klin Med (Mosk); 1996; 74(1):45-7. PubMed ID: 8649009
[No Abstract] [Full Text] [Related]
[Next] [New Search]
